|
|
SmallCapReview.com - Small Cap Of The Day - CANF Can-Fite BioPharma (NYSE: CANF) $2.64. Today announced development of its drug candidate CF102, which is currently in Phase II trials for hepatocellular carcinoma (HCC) the most common form of liver cancer, will be expanded into treatment for non-alcoholic steatohepatitis (NASH). NASH is characterized by excess fat in the liver along with inflammation and liver damage. It resembles alcoholic liver disease; however, it occurs in people who drink little or no alcohol. If untreated, NASH can lead to cirrhosis and liver cancer. According to the National Institutes Of Health, NASH affects between 2% and 5% of Americans and the prevalence of NASH has been increasing, potentially due to increasing rates of obesity and diabetes. By 2025, Deutsche Bank estimates the addressable pharmaceutical market for NASH will reach $35-40 billion in size. As of today, while there are several companies developing drugs to treat NASH that are in preclinical and clinical development, no specific U.S. Food and Drug Administration (FDA) approved treatment for NASH exists. "Results
from our recently concluded preclinical study of CF102 in liver disease revealed
compelling data. Based on these findings, we've filed a patent for CF102 in the
treatment of NASH," stated Can-Fite CEO Dr. Pnina Fishman. "Because
the prevalence of NASH continues to grow and no treatment currently exists, our
data support the development of CF102 for the treatment of NASH."
| |||||||||||||||||||||
